Delhi High Court’s Demand for Centre’s Reply on Rare‑Disease Funding Raises Questions of State Duty, Judicial Review and Health‑Care Rights

A petition has been filed in the Delhi High Court wherein the petitioner seeks an order directing the Union Government, referred to as the Centre, to provide forty lakh rupees in financial assistance for a bone marrow transplant that is required to treat a three‑year‑old girl diagnosed with a rare disease, and the nature of the request centers on securing life‑saving medical care for a minor who otherwise lacks the means to obtain such specialised treatment. The High Court, upon reviewing the petition, issued a notice seeking the Centre’s response to the funding request, thereby initiating a procedural step in which the executive is called upon to explain its position on whether it bears a legal obligation to allocate the requested sum for the specific medical procedure and to justify any policy considerations that may influence its decision. The procedural posture of the case now rests on the forthcoming reply from the Centre, which will be examined by the court for adequacy, legal basis, and conformity with any applicable statutory frameworks governing the allocation of public resources for health‑care interventions involving rare diseases, and the petition underscores the broader issue of governmental responsibility in addressing high‑cost treatments for vulnerable children. The outcome of this interlocutory interaction is poised to influence future claims by individuals seeking state‑funded assistance for costly medical procedures, as the High Court’s direction to obtain a response reflects the judiciary’s willingness to scrutinise executive actions where fundamental medical needs intersect with public‑policy decisions affecting the right to health of minors.

One question is whether the Delhi High Court possesses the jurisdiction to entertain a petition seeking a directive against the Centre for allocating funds to a specific medical procedure for a minor, and the answer may depend on the principles governing public‑interest litigation and the scope of constitutional protections that have been interpreted to encompass the right to health. The answer may also hinge on whether the court views the request as falling within its equitable jurisdiction to issue a writ compelling the executive to act, or alternatively as a matter reserved for the policy‑making discretion of the Union Government, and this distinction will shape the procedural pathway of the case. If the court determines that it has the authority to order the Centre to provide the requested funding, the subsequent analysis will have to balance the need for judicial enforcement of health‑related rights against the principle of separation of powers inherent in the Indian constitutional framework. Finally, the court’s determination on jurisdiction will set a precedent for how High Courts address similar funding pleas, influencing the procedural posture of future health‑related public‑interest petitions.

Perhaps the more important legal issue is whether the Union Government bears a positive duty to allocate financial resources for rare‑disease treatment in the absence of an explicit statutory provision, and this may be examined through the lens of the principle that the state must protect life and health, especially of children, even if such protection is not expressly codified in legislation. A fuller legal assessment would consider prior judicial pronouncements that have read a right to health into broader guarantees, and whether those precedents can be extended to create an enforceable entitlement to governmental funding for high‑cost medical interventions required for survival. The analysis may also explore whether the absence of a specific statutory scheme imposes a discretionary rather than mandatory obligation on the Centre, and how that distinction influences the court’s willingness to intervene in matters of health‑care financing for rare diseases. Consequently, the delineation between discretionary and mandatory duties will have lasting impact on the allocation of resources for rare diseases, guiding both legislative reforms and executive policy formulation.

Another possible view is whether the Centre’s eventual response must satisfy the requirements of reasoned decision‑making and disclose the factual and policy basis for any refusal to fund the transplant, and a fuller legal assessment would require clarity on whether principles of natural justice and procedural fairness apply to administrative determinations concerning the allocation of public health‑care funds. If the response lacks sufficient justification, the petitioners may argue that the omission constitutes a violation of the duty to act fairly, thereby providing the court with grounds to scrutinise the administrative process and possibly compel a more detailed explanation. Such scrutiny would align with established jurisprudence that administrative actions affecting fundamental medical needs must be transparent, proportionate, and based on rational criteria, ensuring that the affected individual's right to life‑saving treatment is not arbitrarily denied. Moreover, a failure to provide a reasoned explanation could invite judicial review on grounds of procedural impropriety, reinforcing the principle that administrative transparency is essential in decisions affecting fundamental health rights.

The issue may require clarification from the court regarding the appropriate remedial measure, whether it should be a mandamus directing the allocation of the requested amount, a directive to formulate a specific scheme for rare‑disease funding, or another equitable decree, and the choice of remedy will hinge upon balancing judicial intervention with respect for executive discretion in policy matters that involve substantial fiscal considerations. The court may also consider ordering an interim direction to ensure that the transplant proceeds without delay while the substantive funding issue is resolved, thereby protecting the child’s immediate health interests pending final determination. Such an interim measure would reflect the court’s equitable jurisdiction to prevent irreparable harm, while also preserving the broader principle that long‑term policy decisions remain within the legislative and executive domain. The selection of an appropriate remedy will therefore reflect the judiciary’s balancing act between ensuring effective relief for the petitioner and preserving the institutional competence of the executive in budgeting and health‑policy decisions.

Perhaps the constitutional concern is whether denying the requested funding infringes an implicit right to health that the judiciary has recognized as part of the broader guarantee of life, and the answer may turn on earlier judgments that have read health into the right to life, even though no specific constitutional article is cited in the present facts. If later facts show that the Centre ultimately refuses the funding, the question may become whether affected parties can invoke collective litigation or seek class‑action relief for other children suffering from rare diseases, and such a development could reshape the legal landscape concerning state responsibility for high‑cost medical interventions and the scope of judicial oversight over health‑care financing. Future claims may therefore rely on the precedent set by this petition to argue for a systematic approach to funding rare‑disease treatments, highlighting the broader implications of the High Court’s current procedural order for the balance between individual rights and governmental resource allocation. In addition, any decision affirming a constitutional dimension to health funding may compel the legislature to enact clearer statutes governing the provision of financial aid for rare‑disease treatments.